Company news

Pfizer has announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the US new drug application and the European marketing authorization application.
 
Generic manufacturer Mylan will not sell Dey L.P., its specialty pharmaceutical division. After a review, the company decided Dey L.P. would be positive for earnings through 2010.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.